- Report
- October 2024
- 194 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 185 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 191 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 190 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 196 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 197 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 194 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 183 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 196 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 197 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 192 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 196 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 193 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 191 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 192 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 195 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 188 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 190 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- October 2024
- 181 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- April 2025
- 179 Pages
Global
From €5324EUR$5,850USD£4,522GBP

The CRISPR market is a subset of the genomics market that focuses on the use of CRISPR-Cas9 technology for gene editing. CRISPR-Cas9 is a powerful tool that enables scientists to make precise changes to the genome of living organisms. This technology has been used to develop treatments for a variety of diseases, as well as to create new crops and livestock. CRISPR-Cas9 technology has also been used to create gene drives, which are designed to spread a desired trait through a population.
The CRISPR market is highly competitive, with a number of companies offering products and services related to gene editing. These companies include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, and ERS Genomics. These companies are developing a range of products, from gene editing tools to gene therapies, and are working to make CRISPR-Cas9 technology more accessible and affordable. Show Less Read more